TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →. With ReMuS Registry.
Phase
—
Status
Completed
Study type
Observational
Enrollment
675actual
Sites
15
Country
Czechia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-01-01 | actual | When the study began enrolling |
| Primary completion | 2025-04-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-30 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Intervention
- Drug: Natalizumab — also filed as Tysabri
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Progressive Multifocal Leukoencephalopathy (PML) who are Taking Natalizumab
measured Up to 6 years
Number of Participants with Serious Adverse Events (SAEs) of Other Opportunistic Infections (OIs) who are Taking Natalizumab
measured Up to 6 years
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed